GE HEALTHCARE TECHNOLOGIES INC.

Drug pipeline (64)

Asset	Stage	Revenue	Status
ADREVIEW	approved	—	—
AMERSCAN MDP KIT	approved	—	—
AMIPAQUE	approved	—	—
BILOPAQUE	approved	—	—
CERETEC	approved	—	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (58)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06398730	phase1	completed	2024-07-02	2026-02-19	GE Healthcare	A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
NCT07472491	phase2_3	recruiting	2026-04-01	2027-11-30	GE Healthcare	A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
NCT00565721	phase2	completed	2007-11-01	2011-10-01	GE Healthcare	A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
NCT00730964	phase4	completed	2008-05-01	2009-10-01	GE Healthcare	A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
NCT00209391	phase3	completed	2003-09-01	2005-08-01	GE Healthcare	A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide

FDA applications (54)

Application

Approved

Type

Applicant

Products

ANDA 215957

2026-06-29

ANDA

GE HEALTHCARE INC

NDA 215168

2024-09-27

NDA

GE HEALTHCARE INC

ANDA 215955

2024-08-05

ANDA

GE HEALTHCARE

NDA 212155

2020-05-20

NDA

GE HEALTHCARE

ANDA 210016

2019-11-01

ANDA

GE HEALTHCARE